KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT3(+) blast phase chronic myeloid leukemia
KF1601 是一种 BCR::ABL1 和 FLT3 的双重抑制剂，可克服 FLT3(+) 急变期慢性粒细胞白血病中的耐药性。
期刊:Molecular Cancer
影响因子:33.9
doi:10.1186/s12943-025-02292-z
Kwon, Hyun-Jin; Shin, Ji Eun; Khan, Amir; Park, So Yeon; Kim, Jiyoung; Lee, Jee-Young; Lee, Doohyun; Lee, Seungyeon; Im, Chun Young; Moon, Heegyum; Han, Ye Ri; Tamai, Minori; Akahane, Koshi; Inukai, Takeshi; Lee, Wonhwa; Kim, Hyelim; Kim, Hong Nam; Ahn, Sung-Min; Park, Hyun Woo; Kim, Dong-Wook
